Here are three points:
1. ReActiv8 aims to provide chronic low back pain relief in adults who have attempted medical management and physical therapy.
2. The CE Mark allows Mainstay Medical to commercialize ReActiv8 in Europe.
3. Mainstay Medical will initially focus its sales and marketing efforts in Germany.
More articles on devices:
Vertebral Technologies launches pedicle screw system: 5 key notes
MiMedx to attend Craig-Hallum Institutional Investor Conference — 3 quick notes
Congress of the Chinese Association of Orthopedic Surgeons Meeting features Misonix’s BoneScalpel — 4 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
